Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Biofrontera AG
  6. News
  7. Summary
    B8F   DE0006046113

BIOFRONTERA AG

(B8F)
  Report
Real-time Estimate Tradegate  -  03:30:00 2023-01-27 am EST
1.390 EUR   +0.72%
01/09Biofrontera Doses First Patient in Phase 3 Actinic Keratosis Clinical Trial
MT
2022Biofrontera AG Announces Executive Appointments to Biofrontera UK Ltd
CI
2022Biofrontera AG Establishes UK Subsidiary to Strengthen Its Sales Activities in the Country
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biofrontera AG Announces Executive Appointments to Biofrontera UK Ltd

12/08/2022 | 07:55am EST

Biofrontera AG announced that it has established a subsidiary to continue the commercialization of Ameluz® in the United Kingdom. The newly founded Biofrontera UK Ltd. Is based in Cambridge, UK and headed by Ms. Pilar de la Huerta and Dr. Montserrat Foguet as Managing Directors.


ę S&P Capital IQ 2022
All news about BIOFRONTERA AG
01/09Biofrontera Doses First Patient in Phase 3 Actinic Keratosis Clinical Trial
MT
2022Biofrontera AG Announces Executive Appointments to Biofrontera UK Ltd
CI
2022Biofrontera AG Establishes UK Subsidiary to Strengthen Its Sales Activities in the Coun..
CI
2022Biofrontera Ag Continues to Adhere to Forecast for Fiscal Year 2022
CI
2022Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended Sep..
CI
2022Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $4.3M, vs. Street Est of $4.3M
MT
2022Biofrontera Says It Has Agreed to Buy Biofrontera AG Options
MT
2022BIOFRONTERA AG : RIGHTS ISSUE: 1 new share @ 1 EUR for 8 existing shares
FA
2022Biofrontera Appoints Fred Leffler as CFO
MT
2022Biofrontera Adopts Shareholder Rights Plan
MT
More news
Financials
Sales 2022 27,0 M 29,3 M 29,3 M
Net income 2022 -42,1 M -45,7 M -45,7 M
Net Debt 2022 - - -
P/E ratio 2022 -2,34x
Yield 2022 -
Capitalization 78,3 M 84,9 M 84,9 M
Capi. / Sales 2022 2,90x
Capi. / Sales 2023 2,30x
Nbr of Employees 102
Free-Float 49,7%
Chart BIOFRONTERA AG
Duration : Period :
Biofrontera AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOFRONTERA AG
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,38 €
Average target price 2,80 €
Spread / Average Target 103%
EPS Revisions
Managers and Directors
Maria del Pilar de la Huerta Martinez Chief Financial Officer
Wilhelm Konrad Zours Chairman-Supervisory Board
Heikki Lanckriet Member-Supervisory Board
Helge Lubenow Member-Supervisory Board
Karlheinz Schmelig Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BIOFRONTERA AG-9.51%85
CSL LIMITED2.91%101 251
SAMSUNG BIOLOGICS CO.,LTD.-3.17%45 824
BIOGEN INC.5.42%42 037
WUXI BIOLOGICS (CAYMAN) INC.19.30%38 535
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.19.07%24 669